There are currently 147 active clinical trials seeking participants for Melanoma research studies. The states with the highest number of trials for Autism participants are California, Texas, Florida and Pennsylvania.
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
NCT02830724
Recruiting
Background: In a new cancer therapy, researchers take a person s blood, select a certain white blood cell to grow in the lab, and then change the genes of these cells using a virus. The cells are then given back to the person. This is called gene transfer. For this study, researchers will modify the person s white blood cells with anti-CD70. Objectives: To see if a gene transfer with anti-CD70 cells can safely shrink tumors and to be certain the treatment is safe. Eligibility: Adults age 18... Read More
Gender:
All
Ages:
Between 18 years and 72 years
Trial Updated:
04/27/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Pancreatic Cancer, Renal Cell Cancer, Breast Cancer, Melanoma, Ovarian Cancer
Register for Updates
Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma
NCT04119024
Recruiting
This phase I trial studies the side effects and best dose of modified immune cells (IL13Ralpha2 CAR T cells) after a chemotherapy conditioning regimen for the treatment of patients with stage IIIC or IV melanoma. The study agent is called IL13Ralpha2 CAR T cells. T cells are a special type of white blood cell (immune cells) that have the ability to kill tumor cells. The T cells are obtained from the patients own blood, grown in a laboratory, and modified by adding the IL13Ralpha2 CAR gene. The I... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/26/2024
Locations: City of Hope Comprehensive Cancer Center, Duarte, California +1 locations
Conditions: Clinical Stage IV Cutaneous Melanoma AJCC v8, IL13RA2 Positive, Metastatic Melanoma, Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV, Melanoma, Uveal Melanoma, Acral Melanoma, Neuroendocrine Tumors, Paraganglioma, Adrenocortical Carcinoma, Pancreatic Neuroendocrine Tumor, Thyroid Cancer, Breast Cancer, Lung Adenocarcinoma, Head and Neck Squamous Cell Carcinoma
Register for Updates
Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors
NCT05909995
Recruiting
The purpose of this study is to characterize the safety, tolerability, PK, and efficacy of INCB 99280 in combination with ipilimumab in participants with select solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Hgb - Hospital Giovanni Battista - Mae de Deus Center, Fullerton, California +27 locations
Conditions: Melanoma, Hepatocellular Carcinoma (HCC), Renal Cell Carcinoma (RCC), Microsatellite Instability - High (MSI-H), Mismatch Repair Deficient (dMMR), Colorectal Carcinoma (CRC)
Register for Updates
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)
NCT06099782
Recruiting
The purpose of this study is to evaluate participant preference for coformulated hyaluronidase/pembrolizumab (MK-3475A) administered subcutaneously (SC) over pembrolizumab (MK-3475) administered intravenously (IV) in participants with multiple tumor types. There will be no hypothesis testing in this study.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Alaska Oncology and Hematology ( Site 0121), Anchorage, Alaska +35 locations
Conditions: Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma
Register for Updates
A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma
NCT06054555
Recruiting
The purpose of this study is to assess the efficacy, safety, and immunogenicity of ABP 206 compared with Nivolumab in Subjects with Treatment-Naïve Unresectable or Metastatic Melanoma.
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
04/24/2024
Locations: Ft Wayne Med Oncology Hematology, Fort Wayne, Indiana +77 locations
Conditions: Melanoma
Register for Updates
A Clinical Study of V940 Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
NCT05933577
Recruiting
The purpose of this study is to learn if V940 which is an individualized neoantigen therapy (INT; formerly, called messenger ribonucleic acid [mRNA]-4157) with pembrolizumab (MK-3475) is safe and prevents cancer from returning in people with high-risk melanoma. Researchers want to know if V940 with pembrolizumab is better than receiving pembrolizumab alone at preventing the cancer from returning.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Highlands Oncology Group ( Site 1943), Springdale, Arkansas +128 locations
Conditions: Melanoma
Register for Updates
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
NCT04291105
Recruiting
This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will enroll patients with three distinct separate tumor cohorts. The cancers types are colorectal, head and neck carcinoma, and melanoma that are progressing on CPI treatment.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/22/2024
Locations: Mayo Clinical, Phoenix, Arizona +25 locations
Conditions: Melanoma, Head and Neck Squamous Cell Carcinoma, Colo-rectal Cancer
Register for Updates
Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma
NCT04594187
Recruiting
This phase II trial seeks to determine the role of nodal radiation therapy after sentinel lymph node biopsy (SLNB) for patients with high risk sentinel lymph node positive melanoma who are planned for immunotherapy without completion lymph node dissection. Prior studies of patients with more advanced melanoma have shown nodal radiation therapy can decrease the risk of nodal recurrence but it is not known if this same benefit will be seen in patients with high risk sentinel lymph node positive di... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/22/2024
Locations: Baptist - MD Anderson Cancer Center, Jacksonville, Florida +2 locations
Conditions: Melanoma
Register for Updates
The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN)
NCT04866810
Recruiting
Background: The gut microbiome is made up microorganisms. These include the good and bad bacteria that live in the digestive tract. Changes in the gut microbiome have been linked to the development of cancer. Researchers want to learn more about the effects of modulating the microbiome with diet and exercise. Objective: To see if nutritional intake and physical activity change the gut microbiome in people with melanoma. Eligibility: Adults age 18 and older with previously untreated melanoma... Read More
Gender:
All
Ages:
Between 18 years and 120 years
Trial Updated:
04/20/2024
Locations: Loma Linda University, Loma Linda, California +1 locations
Conditions: Melanoma
Register for Updates
Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors
NCT04609566
Recruiting
This trial will find out whether brentuximab vedotin and pembrolizumab work together to treat different types of cancer. There will be several different types of cancer studied in the trial. The cancer must have spread to other parts of the body (metastatic). The study will also find out what side effects occur. A side effect is anything the treatment does besides treat cancer. This is a multi-cohort study.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/19/2024
Locations: Arizona Oncology Associates, PC - HOPE, Tucson, Arizona +32 locations
Conditions: Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
Register for Updates
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
NCT05973487
Recruiting
TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous participant-derived T cells are engineered to express a T cell receptor that recognizes cancer-associated antigens presented on specific Human Leukocyte Antigen (HLA) molecules. This is a multi-center, non-randomized, multi-arm, open-label, basket study evaluating the safety and preliminary efficacy of single and repeat dose regimens of TCR'Ts as monotherapies and as T-Plex combinations after ly... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/19/2024
Locations: HonorHealth Research and Innovation Institute, Scottsdale, Arizona +13 locations
Conditions: Head and Neck Cancer, Cervical Cancer, Non-small Cell Carcinoma, Melanoma, Ovarian Cancer, Anogenital Cancers, HPV - Anogenital Human Papilloma Virus Infection, HPV-Related Cervical Carcinoma, HPV-Related Carcinoma, HPV-Related Squamous Cell Carcinoma, HPV-Related Malignancy, HPV-Related Adenocarcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Adenosquamous Carcinoma, HPV-Associated Vaginal Adenocarcinoma, HPV-Related Endocervical Adenocarcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Verrucous Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma, HPV Positive Rectal Squamous Cell Carcinoma
Register for Updates
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
NCT05581004
Recruiting
This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of RO7502175 when administered as a single agent and in combination with atezolizumab in adult participants with locally advanced or metastatic solid tumors, including non-small-cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), melanoma, triple-negative breast cancer (TNBC), esophageal cancer, gastric cancer, cervical cancer, urothelial carcinoma (UC), clear... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/19/2024
Locations: Stanford University', San Francisco, California +32 locations
Conditions: Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC, Melanoma, TNBC, Esophageal Cancer, Gastric Cancer, Cervical Cancer, Urothelial Carcinoma, Clear Cell RCC, HCC
Register for Updates